CoChat
Sign Up
Cited by 806

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Cederquist, Lynette, Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey, Cooper, Harry S., Deming, Dustin, Engstrom, Paul F., Garrido-Laguna, Ignacio, Grem, Jean L., Grothey, Axel, Hochster, Howard S., Hoffe, Sarah, Hunt, Steven, Kamel, Ahmed, Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcahy, Mary F., Murphy, James D., Nurkin, Steven, Saltz, Leonard, Sharma, Sunil, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Wuthrick, Evan, Gregory, Kristina M., Freedman-Cass, Deborah A.·2018·Journal of the National Comprehensive Cancer Network
DOI 10.6004/jnccn.2018.0021PMC PMC10184502
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2018.0021

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 42

  1. [1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7– 30. 29313949
  2. [2]Cheng L, Eng C, Nieman LZ, Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011; 34: 573– 580. 21217399
  3. [3]Siegel RL, Miller KD, Fedewa SA, Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 67: 177– 193. 28248415
  4. [5]Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212– 236. 21685461
  5. [6]Edwards BK, Ward E, Kohler BA, Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544– 573. 19998273 PMC3619726
  6. [7]Bailey CE, Hu CY, You YN, Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 2015; 150: 17– 22. 25372703 PMC4666003
  7. [9]Kopetz S, McDonough SL, Lenz HJ, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]. J Clin Oncol 2017; 35(Suppl):Abstract 3505. PMC8462593 33356422
  8. [10]Benson AB III, Venook AP, Al-Hawary MM, NCCN Guidelines for Colon Cancer. Version 2. 2018. Accessed March 17, 2018. To view the most recent version of these guidelines, visit NCCN.org. PMC10184502 29632055
  9. [11]Boland GM, Chang GJ, Haynes AB, Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 2013; 119: 1593– 1601. 23280510 PMC3889139
  10. [12]Booth CM, Nanji S, Wei X, Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw 2016; 14: 47– 56. 26733554
  11. [13]Casadaban L, Rauscher G, Aklilu M, Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 2016; 122: 3277– 3287. 27417445 PMC5073024
  12. [14]Hines RB, Barrett A, Twumasi-Ankrah P, Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. J Natl Compr Canc Netw 2015; 13: 51– 60. 25583769
  13. [15]Andre T, Boni C, Mounedji-Boudiaf L, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343– 2351. 15175436
  14. [17]Haller DG, Tabernero J, Maroun J, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465– 1471. 21383294
  15. [18]Schmoll HJ, Cartwright T, Tabernero J, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102– 109. 17194911
  16. [19]Kuebler JP, Wieand HS, O’Connell MJ, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198– 2204. 17470851
  17. [20]Andre T, Boni C, Navarro M, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109– 3116. 19451431
  18. [21]Sargent DJ, Marsoni S, Monges G, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219– 3226. 20498393 PMC2903323
  19. [22]Kim JE, Hong YS, Kim HJ, Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol 2015; 22(Suppl 3): S630– 637. 26271397
  20. [23]McCleary NJ, Meyerhardt JA, Green E, Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600– 2606. 23733765 PMC3699725
  21. [24]Yothers G, O’Connell MJ, Allegra CJ, Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768– 3774. 21859995 PMC3188282
  22. [25]Tournigand C, Andre T, Bonnetain F, Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353– 3360. 22915656
  23. [26]Pectasides D, Karavasilis V, Papaxoinis G, Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer 2015; 15: 384. 25956750 PMC4445286
  24. [27]Cassidy J, Clarke S, Diaz-Rubio E, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006– 2012. 18421053
  25. [31]Overman MJ, Lonardi S, Wong KYM, Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36: 773– 779. 29355075
  26. [32]Moretto R, Cremolini C, Rossini D, Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist 2016; 21: 988– 994. 27382031 PMC4978565
  27. [35]Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104– 117. 24639052
  28. [36]Morris V, Overman MJ, Jiang ZQ, Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 2014; 13: 164– 171. 25069797 PMC4266576
  29. [37]Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23: 6771– 6790. 16170185
  30. [38]Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs 2012; 72: 2207– 2222. 23116250
  31. [40]Kopetz S, Desai J, Chan E, Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33: 4032– 4038. 26460303 PMC4669589
  32. [41]Prahallad A, Sun C, Huang S, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100– 103. 22281684
  33. [42]Corcoran RB, Ebi H, Turke AB, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227– 235. 22448344 PMC3308191
  34. [43]Pietrantonio F, Petrelli F, Coinu A, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587– 594. 25673558
  35. [44]Yang H, Higgins B, Kolinsky K, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779– 789. 22180495
  36. [45]Hong DS, Morris VK, El Osta B, Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 2016; 6: 1352– 1365. 27729313 PMC5562357
  37. [46]Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book 2015: 177– 186. 25993155
  38. [50]Silkin SV, Startsev SS, Krasnova ME, Complete clinical response of BRAF-mutated cholangiocarcinoma to vemurafenib, panitumumab, and irinotecan. J Gastrointest Cancer 2016; 47: 502– 505. 26687137
  39. [51]Corcoran RB, Atreya CE, Falchook GS, Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33: 4023– 4031. 26392102 PMC4669588
  40. [52]Falchook GS, Long GV, Kurzrock R, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893– 1901. 22608338 PMC4109288
  41. [53]Hong DS, Vence L, Falchook G, BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012; 18: 2326– 2335. 22355009
  42. [54]Williams CB, McMahon C, Ali SM, A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther 2015; 8: 3561– 3564. 26664139 PMC4671814

Cited by

Sorted by citations

Metadata

Authors
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., Garrido-Laguna, I., Grem, J. L., Grothey, A., Hochster, H. S., Hoffe, S., Hunt, S., Kamel, A., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Murphy, J. D., Nurkin, S., Saltz, L., Sharma, S., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Wuthrick, E., Gregory, K. M., & Freedman-Cass, D. A.
Venue
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Published
2018-04
Volume
16
Issue
4
Pages
359-369
ISSN
  • 1540-1405
  • 1540-1413
DOI
10.6004/jnccn.2018.0021
PMC
PMC10184502
Cited by
806
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review